Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 22, 2006

PsychoGenics Expands Huntington Disease Collaboration on Transgenic Mouse Models

  • PsychoGenics expanded its research collaboration with the High Q Foundation and CHDI to phenotype transgenic mouse models of Huntington disease (HD) and evaluate potential therapeutics in those models.

    As part of this collaboration PsychoGenics developed standardized and validated protocols that include assessment of motor and cognitive behavior during disease progression in established transgenic mouse models of HD. Using these mouse models and an adaptive allocation approach to experiment design, whereby compounds are screened and actives are re-screened to increase the statistical power, PsychoGenics developed a high-throughput approach to compound screening, allowing the company to profile the effects of compounds on multiple behavioral domains.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »